Tenofovir alafenamide and Emtricitabine are HIV nucleoside analog reverse transcriptase inhibitors and are indicated as an FDC with other antiretroviral agents for the treatment of HIV-1. FDC of Tenofovir alafenamide and Emtricitabine is indicated in combination with other antiretroviral agents for treatment of HIV-1 infections in adults and adolescents with age 12 years and older.
Sustained efficacy observed with TAF after the switch from TDF, Effective therapy achieved at 90% lower systemic exposure to TFV and Improved renal and bone safety with TAF.